Sattar, Naveed <br/><br/>
Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOMEŽ trial.  [electronic resource] 

 -  Diabetologia  10 2018 
 - 2155-2163 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0428 
<br/><br/><label>Standard No.: </label>10.1007/s00125-018-4702-3  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adipose Tissue--metabolism<br/>Asian People<br/>Aspartate Aminotransferases--metabolism<br/>Benzhydryl Compounds--therapeutic use<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Female<br/>Glucosides--therapeutic use<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Liver--drug effects<br/>Male<br/>Non-alcoholic Fatty Liver Disease--metabolism<br/>Research Design<br/>Sodium-Glucose Transporter 2--metabolism<br/>Sodium-Glucose Transporter 2 Inhibitors--therapeutic use<br/>Sulfonylurea Compounds--therapeutic use<br/>Time Factors<br/>Transaminases--metabolism<br/>Treatment Outcome